
201 - 500 employees
Founded 2008
🧬 Biotechnology
🏥 Healthcare
🔥 Funding within the last year
💰 $100M Post-IPO Equity on 2026-07
Biotechnology • Healthcare
REGENXBIO is a leading clinical-stage biotechnology company focused on developing and commercializing gene therapies using its proprietary NAV® adeno-associated virus (AAV) technology platform. The company is advancing multiple late-stage clinical programs and candidates targeting retinal and rare diseases (examples in its pipeline include ABBV‑RGX‑314 for retinal disease, RGX‑202 for Duchenne, and RGX‑121 for MPS II/ Hunter syndrome). REGENXBIO emphasizes one-time curative treatments, in-house commercial-ready manufacturing, and collaboration with partners and licensees to expand its AAV vector library and therapeutic reach.
📡 We watch REGENXBIO's careers page
Every 2 hours
how often we check
9
roles posted in the last 30 days
Selected: 🆕 Date Added.
🔥 0 minutes ago
VP leading REGENXBIO’s rare disease gene therapy portfolio, P&L, and commercialization strategy. Directing the RGX-202 U.S. launch and cross-functional franchise growth.
🇺🇸 United States – Remote
💵 $289k - $410k / year
🔥 Funding within the last year
💰 $100M Post-IPO Equity on 2026-07
⏰ Full Time
🔴 Lead
👔 Vice President
👻 Ghost score 0%
🔥 0 minutes ago
Medical Science Liaison leader building MSL teams for REGENXBIO’s AAV gene therapy programs. Supporting neuromuscular/DMD clinical development, KOL engagement, advisory boards, and medical congresses.
🇺🇸 United States – Remote
💵 $206k - $340k / year
🔥 Funding within the last year
💰 $100M Post-IPO Equity on 2026-07
⏰ Full Time
🟠 Senior
👨⚕️ Medical Director
👻 Ghost score 0%
🔥 0 minutes ago
Market Development Director advancing REGENXBIO’s rare disease gene therapy launches in the Southeast. Leading treatment-center engagement, market access, and regional commercial strategy.
🐊 Florida, South Carolina – Remote
💵 $187k - $265k / year
🔥 Funding within the last year
💰 $100M Post-IPO Equity on 2026-07
⏰ Full Time
🔴 Lead
👔 Director
👻 Ghost score 0%
🔥 0 minutes ago
Head of Sales leading REGENXBIO’s commercial field strategy for rare-disease gene therapies. Driving DMD market growth, patient access, launch readiness, and sales execution.
🇺🇸 United States – Remote
💵 $262k - $373k / year
🔥 Funding within the last year
💰 $100M Post-IPO Equity on 2026-07
⏰ Full Time
🔴 Lead
🤑 Sales
👻 Ghost score 0%
🔥 0 minutes ago
Director leading commercial data, advanced analytics, and forecasting at REGENXBIO, a gene therapy company. Building launch-readiness models, forecasts, dashboards, and decision-support capabilities.
🇺🇸 United States – Remote
💵 $196k - $265k / year
🔥 Funding within the last year
💰 $100M Post-IPO Equity on 2026-07
⏰ Full Time
🔴 Lead
👔 Director
👻 Ghost score 0%